Safety, regulatory, device, AI/GxP and compliance updates with role-specific action guidance for QPPV, Signal, Labeling, PV Ops and Device Vigilance.
Ema update requires triage for Label Governance, Risk Management, AI / GxP Governance; confirm local obligations and document follow-up actions.
5 SOPs may need review
Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.
2 SOPs may need review
1) Add/confirm the TGA 'medical device post-market monitoring and safety updates' page as a tracked regulatory intelligence source for routine review. 2) Cross-check internal Australia device vigilance SOPs/work instructions against TGA guidance on sponsor/manufacturer post-market responsibilities and document any gaps for CAPA/change control as needed.
5 SOPs may need review
Pick the role that matches your work. We'll send a weekly summary of the updates that impact your workflow — already impact-assessed.
Oversight-level updates on safety signals, inspections, AI/GxP, vendor governance, and country compliance triggers.
Weekly. Unsubscribe anytime. You can switch roles later from your inbox.